StockpollyBeta
Get App
Popularity #875
ERAS · NASDAQ · Biotechnology

Erasca (ERAS)

Develops pan-RAS and pan-KRAS therapies for RAS/MAPK-driven solid tumors.

$15.60
After hours+0.05 (+0.35%)
At close$15.55(+3.36%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue011001000110
Gross profit0−1−100−1000−1−10
353338683735363835323748
Research & development252529332826262122232736
989121091091091112
Selling & marketing00−1000000000
General & administrative9010121001091091112
Other expenses0002300082−1−10
Operating income−35−34−39−68−37−36−36−38−35−33−38−48
4445635444−1464
Interest income444565544444
Other non-operating income0−4−4−23−6−3−5−8−4−4146−4
Income before tax−30−30−35−63−31−32−31−34−31−29−183−44
Net income from continuing operations−30−30−35−63−31−32−31−34−31−29−183−44
Net income−30−30−35−63−31−32−31−34−31−29−183−44
EPS, basic−$0.20−$0.20−$0.23−$0.29−$0.11−$0.11−$0.11−$0.12−$0.11−$0.10−$0.60−$0.14
EPS, diluted−$0.20−$0.20−$0.23−$0.29−$0.11−$0.11−$0.11−$0.12−$0.11−$0.10−$0.60−$0.14
Weighted average shares, basic150151151218282283283283284284304311
Weighted average shares, diluted150151151218282283283283284284304311
EBITDA−34−29−34−44−30−31−30−30−30−28−183−43
Depreciation & amortization111111111111
EBIT−35−30−35−45−31−32−31−31−31−29−183−44